Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.52 |
| ▸ | FLT1 | P17948 | 7/20 | 0.52 |
| ▸ | EGFR | P00533 | 11/20 | 0.50 |
| ▸ | FLT4 | P35916 | 4/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.48 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KIF5B | P33176 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19100062 | 0.93 | EGFR (0.53) | KDRFLT1EGFRFLT4FGFR1 | |
| SCHEMBL17967491 | 0.92 | KDR (0.61) | KDRFLT1EGFRFLT4FGFR1 | |
| SCHEMBL18012077 | 0.88 | KDR (0.66) | KDRFLT1EGFRFLT4FGFR1 | |
| SCHEMBL18012088 | 0.88 | KDR (0.66) | KDRFLT1EGFRFLT4FGFR1 | |
| SCHEMBL19124213 | 0.87 | KCNH2 (0.55) | EGFRERBB2 | |
| SCHEMBL18013052 | 0.87 | KDR (0.52) | KDRFLT1EGFRFLT4FGFR1 | |
| SCHEMBL19125349 | 0.85 | KDR (0.49) | KDRFLT1EGFRFLT4FGFR1 | |
| SCHEMBL17967489 | 0.84 | EGFR (0.57) | KDRFLT1EGFRFLT4FGFR1 | |
| SCHEMBL159404 | 0.83 | KDR (0.64) | KDRFLT1EGFRFLT4FGFR1 | |
| SCHEMBL19124188 | 0.83 | KDR (0.48) | KDRFLT1EGFRFLT4FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2019-01-17 | — | — | US | disclosed |
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2019-01-17 | — | — | US | disclosed |
| WO-2017117680-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016689-A1 | NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | KDR 202/4885FLT1 34/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.